TET protein inhibitors: Potential and limitations

Investor logo
Investor logo
Investor logo

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

KAPLÁNEK Robert KEJÍK Zdeněk HAJDUCH Jan VESELÁ Kateřina KUČNIROVÁ Kateřina SKALIČKOVÁ Markéta VENHAUEROVÁ Anna HOSNEDLOVÁ Božena HROMÁDKA Róbert DYTRYCH Petr NOVOTNÝ Petr ABRAMENKO Nikita ANTONYOVÁ Veronika HOSKOVEC David BABULA Petr MASAŘÍK Michal MARTÁSEK Pavel JAKUBEK Milan

Year of publication 2023
Type Article in Periodical
Magazine / Source Biomedicine & Pharmacotherapy
MU Faculty or unit

Faculty of Medicine

Citation
web https://www.sciencedirect.com/science/article/pii/S0753332223011150?via%3Dihub
Doi http://dx.doi.org/10.1016/j.biopha.2023.115324
Keywords TET protein; Inhibitor; Cancer; Therapy; Mitochondria
Attached files
Description TET proteins (methylcytosine dioxygenases) play an important role in the regulation of gene expression. Dysregulation of their activity is associated with many serious pathogenic states such as oncological diseases. Regulation of their activity by specific inhibitors could represent a promising therapeutic strategy. Therefore, this review describes various types of TET protein inhibitors in terms of their inhibitory mechanism and possible applicability. The potential and possible limitations of this approach are thoroughly discussed in the context of TET protein functionality in living systems. Furthermore, possible therapeutic strategies based on the inhibition of TET proteins are presented and evaluated, especially in the field of oncological diseases.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info